Skip to main content
Premium Trial:

Request an Annual Quote

Felix Frueh, Douglas Kell, Fred Tenover

Premium
Medco Health Solutions has appointed Felix Frueh to be VP of research and development, personalized medicine.
 
Frueh formerly was associate director for genomics at the US Food and Drug Administration’s Office of Clinical Pharmacology in the Center for Drug Evaluation and Research. He also was chair of the FDA’s Interdisciplinary Pharmacogenomics Review Group.
 
Prior to joining the FDA, Frueh was a managing partner at Stepoutside Consulting, research director for pharmacogenomics at Transgenomic, and an assistant director in the department of biology at Protogene Laboratories.
 
Before working in industry, he was an assistant professor in Georgetown University’s department of pharmacology.
 

 
Douglas Kell has been tapped as chief executive of the UK’s Biotechnology and Biological Sciences Research Council for a four-year period.
 
Kell is professor of bioanalytical science at the University of Manchester, and he is director of the Manchester Centre for Integrative Systems Biology, where he will continue to work one day a week when he takes on his new position in October.
 

 
Fred Tenover will step into the role of senior director of scientific affairs for Cepheid. He will act as a liaison with the infection-control community and he will run the company’s Healthcare Associated Infection Consortium program.
 
Tenover currently is distinguished consultant and director of the Office of Antimicrobial Resistance at the Centers for Disease Control and Prevention. He is also director of the CDC/World Health Organization Collaborating Center for Global Antimicrobial Resistance Monitoring, and adjunct professor in the department of epidemiology at Emory University’s School of Public Health.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.